Drugs /

xl888

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally bioavailable, ATP-competitive, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor XL888 specifically binds to Hsp90, inhibiting its chaperone function and promoting the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival; inhibition of tumor cell proliferation may result. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins, including Her-2 and Met.

Clinical Trials

View Clinical Trials for xl888

Xl888 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating xl888, 1 is phase 1 (1 open).

Adenocarcinoma of the gastroesophageal junction, cholangiocarcinoma, and colorectal adenocarcinoma are the most common diseases being investigated in xl888 clinical trials [2].

Drug Details

Synonyms [2]:
hsp90 inhibitor xl888, heat shock protein 90 inhibitor xl888
Drug Categories [2]:
HSP90 inhibitors
Drug Target(s) [2]:
HSP90AA1, HSP90AB1
NCIT ID [1]:
C79835

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.